Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world

* ASTRUM-005 is the first study to demonstrate that PD-1 inhibitors plus chemotherapy can improve survival for patients with ES-SCLC. * In ASTRUM-005, serplulimab combined with chemotherapy achieved by far the longest OS in first-line immunotherapy for ES-SCLC. Compared with chemotherapy, the...

2022-09-28 21:00 3695

ICHNOS SCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN STUDY FOR ISB 1442

First patient dosed with novel biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47 NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in oncology, today anno...

2022-09-28 20:30 1711

ABILITY DIABETES GLOBAL - A Landmark RCT in the field of PCI for patients with DM, completes Enrolment

TAMPA, Fla., Sept. 28, 2022 /PRNewswire/ -- ABILITY DIABETES-GLOBAL (ADG), is the World's largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing head-to-head the Sirolimus eluting ste...

2022-09-28 20:29 3226

ABILITY DIABETES GLOBAL - A Landmark RCT in the field of PCI for patients with DM, completes Enrolment

The IND application of Biosyngen BRG01 Therapy was accepted by CDE

GUANGZHOU, China, Sept. 28, 2022 /PRNewswire/ -- The IND application of Biosyngen BRG01 Therapy has been accepted for review by the Center for Drug Evaluation,China (CXSL2200487)（ https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d

2022-09-28 18:05 5033

Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost

SINGAPORE, Sept. 28, 2022 /PRNewswire/ -- On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a base to develop the company's immunotherapy assets to address unmet needs in cancer treatment. Located in Solaris @ Tai Seng, this 1,300 square metres faci...

2022-09-28 17:34 6490

Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology

CAMBRIDGE, England and COPENHAGEN, Denmark, Sept. 28, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S ("Contera") are pleased to announce a strategic drug discovery collaboration on an undisclosed target. Under the terms of the...

2022-09-28 16:00 2463

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency LEIDEN, The Netherlands, Sept. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharmi...

2022-09-28 13:00 3563

Chugai Pharma Taiwan Awarded at the Asia Responsible Enterprise Awards 2022 for 'Cycling for Charity' under Social Empowerment Category

SINGAPORE, Sept. 28, 2022 /PRNewswire/ -- The Asia Responsible Enterprise Awards (AREA) 2022 is pleased to honor 72 exemplary award recipients for championing ESG to build a resilient world and a sustainable future for all. The AREA is the most prominent CSR recognition program across Asia initia...

2022-09-28 12:30 2216

ETANA HAS SECURED B ROUND FINANCING

JAKARTA, Indonesia, Sept. 28, 2022 /PRNewswire/ -- PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured B round of financing led by Yunfeng Capital and followed by HighLight Capital. This round of financing will be mainly used for further strengthening ...

2022-09-28 09:00 6310

Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

-- After the pre-Phase III clinical trial meeting with Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) in June 2022, the pathway to the registration, including patient population, dose, treatment duration, etc. of ASC22 (Envafolimab) for functional cure of...

2022-09-28 08:10 3630

Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a pivotal Phase III registration study that will bridge ...

2022-09-28 06:50 2427

First Patient in Australia Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent

MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose inAustralia of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as...

2022-09-28 05:00 3062

TargEDys and Inoliva announce they have entered a distribution partnership to bring Satylia® to Turkey

LONGJUMEAU, France, Sept. 27, 2022 /PRNewswire/ -- TargEDys and Inoliva, an affiliate ofAbdi Ibrahim, have signed an exclusive marketing and distribution agreement to bring Satylia, a food supplement based on the next-generation probioticHafnia alvei HA4597, to the Turkish market. Satylia, al...

2022-09-27 17:15 3162

Sciwind Biosciences and SynerK Enter into Research Partnership to Discover and Develop Novel siRNA Therapeutics

The partnership combines Sciwind's expertise in disease biology and clinical development capabilities with SynerK's proprietary conjugate-based siRNA delivery technology and expertise in developing RNAi therapeutics SAN FRANCISCO, Calif. and HANGZHOU, China, Sept. 27, 2022 /PRNewswire/ -- Sciwin...

2022-09-27 08:00 3178

First Patient Enrolled in ProstACT TARGET Study

MELBOURNE, Australia, Sept. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care inAustralia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix's pro...

2022-09-27 05:00 2845

In commemoration of World Pharmacists Day 2022, P&G Health lauds pharmacists and the role they play in providing whole-of-body healthcare to patients

* P&G Health commemorated World Pharmacists Day 2022 across the Asia Pacific, Middle East, and Africa region through a host of activities * This includes the first ever P&G Health Middle-East Whole-Body Health Symposium over 2 days in which 12,813 participants from 111 countries took part SIN...

2022-09-26 20:08 4051

In commemoration of World Pharmacists Day 2022, P&G Health lauds pharmacists and the role they play in providing whole-of-body healthcare to patients

Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression

* Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects * Findings suggest BRII-296 has potential to provide a safe and effective, one-time injectable treatment option to people wit...

2022-09-26 20:00 3828

Nippon Express (China) Participates in 11th Global Pharmaceutical Cold Chain Summit

TOKYO, Sept. 26, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereinafter "NX China"), a group company of NIPPON EXPRESS HOLDINGS, INC., participated in the three-day 11th Global Pharmaceutical Cold Chain Summit hosted by the China Federation of Logistics & Purchasing and held inChongqi...

2022-09-26 15:00 3327

Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001, a Novel BTK Inhibitor in Development for Treatment of Renal Diseases

Advancement highlights Everest's potential in providing first-in-class therapies to global patients with glomerular disease SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focu...

2022-09-26 08:00 4611

MGC Pharmaceuticals Successfully Developed Herbal-inspired Products for Treatment of Long COVID and COVID-19

LONDON, Sept. 21, 2022 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), is a European based bio-pharma company, focused on developing and supplying affordable (Accessible) and Ethically Produced Plant Inspired Medicines, is helping to solve the mystery of treating Lo...

2022-09-21 17:13 3921

1 ... 136 137 138139140 141 142 ... 184